These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2101 related items for PubMed ID: 27535028

  • 1. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D, Javor E, Lucijanić T, Skelin M.
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [Abstract] [Full Text] [Related]

  • 2. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH.
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ.
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [Abstract] [Full Text] [Related]

  • 4. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW.
    Vasc Health Risk Manag; 2016 Jan; 12():393-405. PubMed ID: 27822054
    [Abstract] [Full Text] [Related]

  • 5. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
    Schubert A, Buchholt AT, El Khoury AC, Kamal A, Taieb V.
    Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
    [Abstract] [Full Text] [Related]

  • 6. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Storgaard H, Gluud LL, Bennett C, Grøndahl MF, Christensen MB, Knop FK, Vilsbøll T.
    PLoS One; 2016 Jun; 11(11):e0166125. PubMed ID: 27835680
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A.
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [Abstract] [Full Text] [Related]

  • 8. Can we go beyond surrogates?
    Drexler A.
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [Abstract] [Full Text] [Related]

  • 9. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
    Levine MJ.
    Curr Diabetes Rev; 2017 Nov; 13(4):405-423. PubMed ID: 27296042
    [Abstract] [Full Text] [Related]

  • 10. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
    Whalen K, Miller S, Onge ES.
    Clin Ther; 2015 Jun 01; 37(6):1150-66. PubMed ID: 25891804
    [Abstract] [Full Text] [Related]

  • 11. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.
    Tang H, Li D, Zhang J, Li Y, Wang T, Zhai S, Song Y.
    Diabetes Obes Metab; 2017 Aug 01; 19(8):1106-1115. PubMed ID: 28240446
    [Abstract] [Full Text] [Related]

  • 12. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.
    Tang HL, Li DD, Zhang JJ, Hsu YH, Wang TS, Zhai SD, Song YQ.
    Diabetes Obes Metab; 2016 Dec 01; 18(12):1199-1206. PubMed ID: 27407013
    [Abstract] [Full Text] [Related]

  • 13. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA, Kuritzky L.
    Postgrad Med; 2014 Oct 01; 126(6):33-48. PubMed ID: 25414933
    [Abstract] [Full Text] [Related]

  • 14. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y.
    Adv Ther; 2019 Oct 01; 36(10):2567-2586. PubMed ID: 31444707
    [Abstract] [Full Text] [Related]

  • 15. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
    Dziuba J, Alperin P, Racketa J, Iloeje U, Goswami D, Hardy E, Perlstein I, Grossman HL, Cohen M.
    Diabetes Obes Metab; 2014 Jul 01; 16(7):628-35. PubMed ID: 24443793
    [Abstract] [Full Text] [Related]

  • 16. POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
    Handelsman Y.
    Endocr Pract; 2015 Sep 01; 21(9):1054-65. PubMed ID: 26132997
    [Abstract] [Full Text] [Related]

  • 17. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
    Carlson CJ, Santamarina ML.
    Expert Opin Drug Saf; 2016 Oct 01; 15(10):1401-12. PubMed ID: 27449721
    [Abstract] [Full Text] [Related]

  • 18. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Lajara R.
    Expert Opin Pharmacother; 2014 Dec 01; 15(17):2565-85. PubMed ID: 25316597
    [Abstract] [Full Text] [Related]

  • 19. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.
    Dandona P, Chaudhuri A.
    Int J Clin Pract; 2017 May 01; 71(5):. PubMed ID: 28440009
    [Abstract] [Full Text] [Related]

  • 20. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
    Chrysant SG.
    Drugs Today (Barc); 2017 Mar 01; 53(3):191-202. PubMed ID: 28447076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 106.